<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic changes frequently occur in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Genomic global hypomethylation, gene promoter region hypermethylation, <z:chebi fb="0" ids="15358">histone</z:chebi> modifications, and alteration of miRNA patterns are major epigenetic changes in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Loss of imprinting(LOI) is associated with colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="3" ids="37445">Folate</z:chebi> deficiency may cause colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> by inducing gene-specific hypermethylation and genomic global hypomethylation </plain></SENT>
<SENT sid="4" pm="."><plain>HDAC inhibitors and demethylating agents have been approved by the FDA for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0001909'>leukemia</z:hpo> treatment </plain></SENT>
<SENT sid="5" pm="."><plain>Non-coding <z:chebi fb="40" ids="33697">RNA</z:chebi> is regarded as another kind of epigenetic marker in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This review is mainly focused on DNA methylation, <z:chebi fb="0" ids="15358">histone</z:chebi> modification, and microRNA changes in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>